Side effects of statins: from pathophysiology and epidemiology to diagnostic and therapeutic implications
Abstract Treatment with statins, inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A
reductase, has proven beneficial preventive effects on cardiovascular events. However …
reductase, has proven beneficial preventive effects on cardiovascular events. However …
[HTML][HTML] Bempedoic acid: for whom and when
Abstract Purpose of Review The aim of creating an orally active non-statin cholesterol-
lowering drug was achieved with bempedoic acid, a small linear molecule providing both a …
lowering drug was achieved with bempedoic acid, a small linear molecule providing both a …
[HTML][HTML] Bempedoic acid in the management of lipid disorders and cardiovascular risk. 2023 position paper of the International Lipid Expert Panel (ILEP)
Cardiovascular disease (CVD) is a chronic non-communicable disease (NCD) and the
predominant cause of morbidity and mortality worldwide. Substantial reductions in the CVD …
predominant cause of morbidity and mortality worldwide. Substantial reductions in the CVD …
[HTML][HTML] Established and emerging lipid-lowering drugs for primary and secondary cardiovascular prevention
Despite treatment with statins, patients with elevated low-density lipoprotein cholesterol
(LDL-C) and triglycerides remain at increased risk for adverse cardiovascular events …
(LDL-C) and triglycerides remain at increased risk for adverse cardiovascular events …
Intensive statin therapy versus upfront combination therapy of statin and ezetimibe in patients with acute coronary syndrome: a propensity score matching analysis …
J Lewek, J Niedziela, P Desperak… - Journal of the …, 2023 - Am Heart Assoc
Background We aimed to compare statin monotherapy and upfront combination therapy of
statin and ezetimibe in patients with acute coronary syndromes (ACSs). Methods and …
statin and ezetimibe in patients with acute coronary syndromes (ACSs). Methods and …
[HTML][HTML] 2023: The year in cardiovascular disease–the year of new and prospective lipid lowering therapies. Can we render dyslipidemia a rare disease by 2024?
In 2023 there are still even 75% of patients over the target of low-density lipoprotein
cholesterol (LDL-C), and hypercholesterolemia is the most common and the worst monitored …
cholesterol (LDL-C), and hypercholesterolemia is the most common and the worst monitored …
[HTML][HTML] 2022: the year in cardiovascular disease–the year of upfront lipid lowering combination therapy
Recent data clearly show that we are extremely ineffective in the use of lipid-lowering
therapy (LLT). Furthermore, the problem seems to be the most serious in the group of …
therapy (LLT). Furthermore, the problem seems to be the most serious in the group of …
[HTML][HTML] Optimal implementation of the 2019 ESC/EAS dyslipidaemia guidelines in patients with and without atherosclerotic cardiovascular disease across Europe: A …
J Brandts, S Bray, G Villa, AL Catapano… - The Lancet Regional …, 2023 - thelancet.com
Background The impact of the stepwise implementation of the 2019 European Society of
Cardiology (ESC)/European Atherosclerosis Society (EAS) treatment algorithm on low …
Cardiology (ESC)/European Atherosclerosis Society (EAS) treatment algorithm on low …
Dyslipidemia treatment and attainment of LDL-cholesterol treatment goals in patients participating in the Managed Care for Acute Myocardial Infarction Survivors …
A Nowowiejska-Wiewióra, K Wita… - Kardiologia Polska …, 2023 - journals.viamedica.pl
Background: Patients after acute myocardial infarction (AMI) are at very high cardiovascular
(CV) risk. Therefore, appropriate management of dyslipidemia with adequate lipid-lowering …
(CV) risk. Therefore, appropriate management of dyslipidemia with adequate lipid-lowering …
[HTML][HTML] Which patients at risk of cardiovascular disease might benefit the most from inclisiran? Polish experts' opinion. The compromise between EBM and …
M Banach, J Kaźmierczak, P Mitkowski… - Archives of Medical …, 2022 - ncbi.nlm.nih.gov
Hypercholesterolemia is the most common cardiovascular (CV) risk factor in Poland,
affecting as many as 21 million people [1, 2]. Unfortunately, most of those affected are not …
affecting as many as 21 million people [1, 2]. Unfortunately, most of those affected are not …